NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) - ...